Literature DB >> 7936809

A new type of defect in the gene for bilirubin uridine 5'-diphosphate-glucuronosyltransferase in a patient with Crigler-Najjar syndrome type I.

S Aono1, Y Yamada, H Keino, Y Sasaoka, T Nakagawa, S Onishi, S Mimura, O Koiwai, H Sato.   

Abstract

Crigler-Najjar syndrome (CN) type I, which is characterized by the complete absence of bilirubin uridine 5'-diphosphate-glucuronosyltransferase (UGT) activity, is inherited as an autosomal recessive trait associated with unconjugated hyperbilirubinemia. Phenobarbital has no effect on the bilirubin concentration in the serum of patients with CN type I. Recently, cDNA for two human liver bilirubin UGT (UGT1A and UGT1D) were isolated, and their genetic organization was determined. The UGT1A (UGT1*1) and UGT1D (UGT1*4) genes each have a unique exon 1, whereas exons 2-5 are common to both genes. It has been predicted that some defect in the exons common to both genes is responsible for the absence of UGT1A and UGT1D activities in CN type I, and five cases with such a mutation have been reported. We describe here a new type of defect in the gene for bilirubin UGT in a patient with CN type I, namely, an abnormality in the exon 1 that is characteristic of the UGT1A gene. This mutation is a single nucleotide substitution, that is, C is changed to A at base position 840 in UGT1A cDNA, and this change results in a stop codon. Our patient is homozygous for the defect, and his nonconsanguineous parents and elder brother, who are clinically normal, are heterozygous for the defective allele. No mutation was detected in any exons of the UGT1D gene. Our results suggest that a homozygous nonsense or deletion mutation is detected not only in the exons common to UGT1A and UGT1D genes but also in unique exon 1 of UGT1A in CN type I.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7936809     DOI: 10.1203/00006450-199406000-00002

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  6 in total

1.  Molecular biology and the diagnosis and treatment of liver diseases.

Authors:  Howard J Worman; Lin Feng; Naoto Mamiya
Journal:  World J Gastroenterol       Date:  1998-06       Impact factor: 5.742

Review 2.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

3.  Intermittent jaundice in patients with acute leukaemia: a common mutation of the bilirubin uridine-diphosphate glucuronosyltransferase gene among Asians.

Authors:  T Kimura; K Akaba; T Ikegami; K Akiba; C Kanazawa; M Katsuura; Y Shimizu; M Imaizumi; C Lin; K Hayasaka
Journal:  J Inherit Metab Dis       Date:  1999-08       Impact factor: 4.982

4.  Transcriptional regulation of human UGT1A1 gene expression through distal and proximal promoter motifs: implication of defects in the UGT1A1 gene promoter.

Authors:  Junko Sugatani; Kousuke Mizushima; Makoto Osabe; Kasumi Yamakawa; Satoru Kakizaki; Hitoshi Takagi; Masatomo Mori; Akira Ikari; Masao Miwa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-03       Impact factor: 3.000

5.  Truncated UDP-glucuronosyltransferase (UGT) from a Crigler-Najjar syndrome type II patient colocalizes with intact UGT in the endoplasmic reticulum.

Authors:  Masahiro Suzuki; Marie Hirata; Miho Takagi; Taiichi Watanabe; Tomohiro Iguchi; Kotaro Koiwai; So Maezawa; Osamu Koiwai
Journal:  J Hum Genet       Date:  2014-01-09       Impact factor: 3.172

Review 6.  UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation.

Authors:  Ryan S Nelson; Nathan D Seligson; Sal Bottiglieri; Estrella Carballido; Alex Del Cueto; Iman Imanirad; Richard Levine; Alexander S Parker; Sandra M Swain; Emma M Tillman; J Kevin Hicks
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.